Truist Securities Maintains Hold on GoodRx Holdings, Raises Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Jailendra Singh has maintained a Hold rating on GoodRx Holdings (NASDAQ:GDRX) and increased the price target from $5.5 to $7.5.
January 12, 2024 | 7:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reaffirmed a Hold rating on GoodRx Holdings while raising the price target from $5.5 to $7.5.
The increase in price target by Truist Securities suggests a positive outlook on GoodRx Holdings' future performance, which could lead to increased investor confidence and a potential short-term rise in the stock price. However, the Hold rating indicates that the analyst does not see significant upside or downside in the near term, hence the score is not higher.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100